Home
AKRO
AKRO News

Latest Akero Therapeutics Inc. (AKRO) News on July 26, 2025

MT Newswires

a month ago

Akero Therapeutics Insider Sold Shares Worth $542,306, According to a Recent SEC Filing

MT Newswires

a month ago

Akero Therapeutics Insider Sold Shares Worth $2,044,940, According to a Recent SEC Filing

Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

GlobeNewswire

2 months ago

Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire

2 months ago

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

Why Akero Therapeutics, Inc. (AKRO) Skyrocketed Today

Insider Monkey

2 months ago

Why Akero Therapeutics, Inc. (AKRO) Skyrocketed Today

MT Newswires

2 months ago

Akero Therapeutics Insider Sold Shares Worth $1,244,455, According to a Recent SEC Filing

MT Newswires

2 months ago

Akero Therapeutics Q1 Net Loss Unchanged

Why Akero Therapeutics (AKRO) Is Among the Best Performing Healthcare Stocks to Buy Now

Insider Monkey

2 months ago

Why Akero Therapeutics (AKRO) Is Among the Best Performing Healthcare Stocks to Buy Now

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

GlobeNewswire

3 months ago

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

MT Newswires

3 months ago

Akero Therapeutics Reports Positive Trial Data for Prospective Cirrhosis Drug

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

GlobeNewswire

3 months ago

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

GlobeNewswire

3 months ago

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

GlobeNewswire

3 months ago

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025

GlobeNewswire

3 months ago

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025

MT Newswires

4 months ago

Akero Therapeutics Insider Bought Shares Worth $8,787,921, According to a Recent SEC Filing

MT Newswires

5 months ago

Akero Therapeutics Insider Sold Shares Worth $2,243,213, According to a Recent SEC Filing

Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?

Zacks

5 months ago

Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?

Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025

Insider Monkey

5 months ago

Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025

MT Newswires

5 months ago

Akero Therapeutics Q4 Loss Unchanged

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire

5 months ago

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Is Akero Therapeutics Inc. (AKRO) the Best Performing Mid Cap Stock to Buy According to Analysts?

Insider Monkey

5 months ago

Is Akero Therapeutics Inc. (AKRO) the Best Performing Mid Cap Stock to Buy According to Analysts?

Akero Therapeutics, Inc. (AKRO): the Best Performing Pharma Stock So Far in 2025

Insider Monkey

5 months ago

Akero Therapeutics, Inc. (AKRO): the Best Performing Pharma Stock So Far in 2025

Akero Therapeutics, Inc. (AKRO): the Best Performing Healthcare Stock So Far in 2025

Insider Monkey

5 months ago

Akero Therapeutics, Inc. (AKRO): the Best Performing Healthcare Stock So Far in 2025

MT Newswires

5 months ago

Akero Therapeutics Insider Sold Shares Worth $1,581,994, According to a Recent SEC Filing

MT Newswires

6 months ago

Akero Therapeutics Insider Bought Shares Worth $9,600,000, According to a Recent SEC Filing

MT Newswires

6 months ago

Akero Therapeutics Insider Sold Shares Worth $538,061, According to a Recent SEC Filing

Why Akero Therapeutics Inc (AKRO) Is Skyrocketing So Far In 2025

Insider Monkey

6 months ago

Why Akero Therapeutics Inc (AKRO) Is Skyrocketing So Far In 2025

Akero Therapeutics Inc. (AKRO): Among The Stocks That Started The Year On A High

Insider Monkey

6 months ago

Akero Therapeutics Inc. (AKRO): Among The Stocks That Started The Year On A High

This Stock Just Doubled in 1 Day -- Is It Still a Buy?

Motley Fool

6 months ago

This Stock Just Doubled in 1 Day -- Is It Still a Buy?

Why Akero Therapeutics (AKRO) Is Among the Best Booming Stocks to Invest in Now?

Insider Monkey

6 months ago

Why Akero Therapeutics (AKRO) Is Among the Best Booming Stocks to Invest in Now?

MT Newswires

6 months ago

UBS Adjusts Price Target on Akero Therapeutics to $109 From $42, Keeps Buy Rating

MT Newswires

6 months ago

Akero Therapeutics Insider Sold Shares Worth $2,734,212, According to a Recent SEC Filing

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire

6 months ago

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Zacks

6 months ago

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

MT Newswires

6 months ago

BofA Securities Upgrades Akero Therapeutics to Buy, $63 Price Target

MT Newswires

6 months ago

Akero Therapeutics Insider Sold Shares Worth $1,742,958, According to a Recent SEC Filing

MT Newswires

6 months ago

Akero Therapeutics Insider Sold Shares Worth $1,646,978, According to a Recent SEC Filing

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

Zacks

6 months ago

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study

Zacks

6 months ago

AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study

BioAge drops obesity drug; Akero, 89bio cash in on MASH data

BioPharma Dive

6 months ago

BioAge drops obesity drug; Akero, 89bio cash in on MASH data

MT Newswires

6 months ago

Akero Therapeutics Prices $350 Million Upsized Public Offering

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire

6 months ago

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Akero’s cirrhosis treatment shows promise in Phase IIb study

Clinical Trials Arena

6 months ago

Akero’s cirrhosis treatment shows promise in Phase IIb study

Why Akero Therapeutics Inc. (AKRO) Surged on Monday

Insider Monkey

6 months ago

Why Akero Therapeutics Inc. (AKRO) Surged on Monday

MT Newswires

6 months ago

Akero Therapeutics Starts $300 Million Stock Offering

Akero Therapeutics Stock Nearly Doubles — Pulling 89bio Higher — On Positive MASH Study

Investor's Business Daily

6 months ago

Akero Therapeutics Stock Nearly Doubles — Pulling 89bio Higher — On Positive MASH Study

Akero Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire

6 months ago

Akero Therapeutics Announces Proposed Public Offering of Common Stock

GuruFocus.com

6 months ago

Akero's Stock Skyrockets 112% After Game-Changing Liver Drug Data

Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results

Investopedia

6 months ago

Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results

Akero Therapeutics Shares Surge 106% as Phase 2b Study Shows Significant Cirrhosis Reversal

GuruFocus.com

6 months ago

Akero Therapeutics Shares Surge 106% as Phase 2b Study Shows Significant Cirrhosis Reversal

Akero Therapeutics Stock Doubles on Liver Data

Barrons.com

6 months ago

Akero Therapeutics Stock Doubles on Liver Data

MT Newswires

6 months ago

Sector Update: Health Care Stocks Mixed Premarket Monday

Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why

Benzinga

6 months ago

Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why

MT Newswires

6 months ago

Sector Update: Health Care

MT Newswires

6 months ago

Akero Therapeutics Says Phase 2b Efruxifermin Study Shows 'Statistically Significant' Reversal of Cirrhosis

MT Newswires

6 months ago

Top Premarket Gainers

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

GlobeNewswire

6 months ago

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

GlobeNewswire

6 months ago

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD

GlobeNewswire

6 months ago

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD

Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

7 months ago

Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

7 months ago

Akero Therapeutics Insider Sold Shares Worth $280,330, According to a Recent SEC Filing

Why Is Akero Therapeutics, Inc. (AKRO) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Insider Monkey

8 months ago

Why Is Akero Therapeutics, Inc. (AKRO) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference

GlobeNewswire

8 months ago

Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference

MT Newswires

8 months ago

Citigroup Initiates Akero Therapeutics at Buy With $65 Price Target

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

GlobeNewswire

8 months ago

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

GlobeNewswire

8 months ago

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

Akero Therapeutics Advances in MASH Treatment Trials

TipRanks

8 months ago

Akero Therapeutics Advances in MASH Treatment Trials

MT Newswires

9 months ago

Akero Therapeutics' Q3 Net Loss Widens

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

9 months ago

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

MT Newswires

9 months ago

Akero Therapeutics Insider Sold Shares Worth $3,438,312, According to a Recent SEC Filing

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH

TipRanks

9 months ago

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

GlobeNewswire

9 months ago

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

State Street Corp's Strategic Reduction in Akero Therapeutics Inc Shares

GuruFocus.com

9 months ago

State Street Corp's Strategic Reduction in Akero Therapeutics Inc Shares

Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin

Insider Monkey

9 months ago

Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin

Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds

Insider Monkey

9 months ago

Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

GlobeNewswire

10 months ago

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

Wellington Management Group LLP's Strategic Acquisition in Akero Therapeutics Inc

GuruFocus.com

10 months ago

Wellington Management Group LLP's Strategic Acquisition in Akero Therapeutics Inc

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

GlobeNewswire

a year ago

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

Akero Therapeutics, Inc. (AKRO): This Small-Cap Healthcare Stock Is A Good Buy Right Now

Insider Monkey

a year ago

Akero Therapeutics, Inc. (AKRO): This Small-Cap Healthcare Stock Is A Good Buy Right Now

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire

a year ago

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

MT Newswires

a year ago

Akero Therapeutics Insider Sold Shares Worth $386,714, According to a Recent SEC Filing

MT Newswires

a year ago

Akero Therapeutics Shares Fall After Q2 Loss Widens

Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated

Zacks

a year ago

Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated

Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down

Zacks

a year ago

Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised

Zacks

a year ago

Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised

MT Newswires

a year ago

Akero Therapeutics Insider Sold Shares Worth $4,381,867, According to a Recent SEC Filing

Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade

Zacks

a year ago

Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade

MT Newswires

a year ago

Wolfe Research Initiates Coverage on Akero Therapeutics With Outperform Rating, $40 Price Target

Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

GlobeNewswire

a year ago

Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

GlobeNewswire

a year ago

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results

Zacks

a year ago

Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire

a year ago

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

MT Newswires

a year ago

Evercore ISI Adjusts Price Target on Akero Therapeutics to $38 From $50, Maintains Outperform Rating

Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...

GuruFocus.com

a year ago

Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...

MT Newswires

a year ago

Akero Therapeutics' Q1 Net Loss Widens; Cash Expected to Fund Operations Into H2 2027

Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference

GlobeNewswire

a year ago

Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

GlobeNewswire

a year ago

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks

Insider Monkey

a year ago

Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks

Share on Social Networks: